<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>RNAi</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Daewoong takes over Turn Bio’s longevity platform from Hanall</title>
      <description>
        <![CDATA[Daewoong Pharmaceutical Co. Ltd. announced after South Korean market hours May 21 that it gained successive rights to Turn Biotechnologies Inc.’s mRNA-based cellular rejuvenation platform from Hanall Biopharma Co. Ltd.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731469</guid>
      <pubDate>Tue, 26 May 2026 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731469-daewoong-takes-over-turn-bios-longevity-platform-from-hanall</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/DNA-aging-time.webp?t=1693406596" type="image/jpeg" medium="image" fileSize="349155">
        <media:title type="plain">DNA double helix with sand hour glass</media:title>
      </media:content>
    </item>
    <item>
      <title>Daewoong takes over Turn Bio’s longevity platform from Hanall</title>
      <description>
        <![CDATA[Daewoong Pharmaceutical Co. Ltd. announced after South Korean market hours May 21 that it gained successive rights to Turn Biotechnologies Inc.’s mRNA-based cellular rejuvenation platform from Hanall Biopharma Co. Ltd.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731389</guid>
      <pubDate>Fri, 22 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731389-daewoong-takes-over-turn-bios-longevity-platform-from-hanall</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/DNA-aging-time.webp?t=1693406596" type="image/jpeg" medium="image" fileSize="349155">
        <media:title type="plain">DNA double helix with sand hour glass</media:title>
      </media:content>
    </item>
    <item>
      <title>GSK licenses siRNA asset in $1B deal for Siranbio</title>
      <description>
        <![CDATA[In a deal that could be worth up to $1 billion for Suzhou Siran Biotechnology Co. Ltd. (Siranbio), GSK plc licensed exclusive worldwide rights to the siRNA oligonucleotide SA-030, which has recently entered phase I trials for cardiometabolic disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/731226</guid>
      <pubDate>Tue, 12 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/731226-gsk-licenses-sirna-asset-in-1b-deal-for-siranbio</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/siRNA-structure-model.webp?t=1732119622" type="image/jpeg" medium="image" fileSize="568771">
        <media:title type="plain">Illustration of siRNA structure</media:title>
      </media:content>
    </item>
    <item>
      <title>GSK licenses siRNA asset in $1B deal for Siranbio</title>
      <description>
        <![CDATA[In a deal that could be worth up to $1 billion for Suzhou Siran Biotechnology Co. Ltd. (Siranbio), GSK plc licensed exclusive worldwide rights to the siRNA oligonucleotide SA-030, which has recently entered phase I trials for cardiometabolic disease.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730864</guid>
      <pubDate>Wed, 06 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730864-gsk-licenses-sirna-asset-in-1b-deal-for-siranbio</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/siRNA-structure-model.webp?t=1732119622" type="image/jpeg" medium="image" fileSize="568771">
        <media:title type="plain">Illustration of siRNA structure</media:title>
      </media:content>
    </item>
    <item>
      <title>Bio Korea 2026 kicks off with spotlight on oligonucleotides</title>
      <description>
        <![CDATA[Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and the promise of “programmable,” precision medicine for patients, speakers at Bio Korea 2026 said April 28.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730927</guid>
      <pubDate>Tue, 05 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730927-bio-korea-2026-kicks-off-with-spotlight-on-oligonucleotides</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Researcher-antisense-oligonucleotides.webp?t=1775662140" type="image/jpeg" medium="image" fileSize="579461">
        <media:title type="plain">AI generated image for researcher developing antisense oligonucleotides</media:title>
      </media:content>
    </item>
    <item>
      <title>Madrigal expands MASH pipeline in potential $1B Arrowhead deal</title>
      <description>
        <![CDATA[Three years after Johnson & Johnson handed back rights to an siRNA candidate targeting a genetic driver of metabolic dysfunction-associated steatohepatitis (MASH), Arrowhead Pharmaceuticals Inc. found a new partner in Madrigal Pharmaceuticals Inc., a firm that markets the first U.S. FDA-approved MASH drug, Rezdiffra (resmetirom), and has been building a pipeline in the space.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730851</guid>
      <pubDate>Tue, 05 May 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730851-madrigal-expands-mash-pipeline-in-potential-1b-arrowhead-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Liver-and-DNA.webp?t=1602177503" type="image/png" medium="image" fileSize="311397">
        <media:title type="plain">Liver and DNA</media:title>
      </media:content>
    </item>
    <item>
      <title>Bio Korea 2026 kicks off with spotlight on oligonucleotides</title>
      <description>
        <![CDATA[Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and the promise of “programmable,” precision medicine for patients, speakers at Bio Korea 2026 said April 28.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730686</guid>
      <pubDate>Wed, 29 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730686-bio-korea-2026-kicks-off-with-spotlight-on-oligonucleotides</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Researcher-antisense-oligonucleotides.webp?t=1775662140" type="image/jpeg" medium="image" fileSize="579461">
        <media:title type="plain">AI generated image for researcher developing antisense oligonucleotides</media:title>
      </media:content>
    </item>
    <item>
      <title>Ribo, Diagens tally 2 Hong Kong biotech, medtech IPOs in Q1 2026 </title>
      <description>
        <![CDATA[Ribo Life Science Co. Ltd.’s HK$1.8 billion (US$230 million) raise on Jan. 9 was the sole Chinese biotech IPO on the Hong Kong Stock Exchange in the first quarter (Q1) of 2026, despite a growing backlog of more than 70 filings from China life science firms in 2025. Among med-tech companies, Hangzhou Diagens Biotechnology Co. Ltd. debuted with a $101 million Hong Kong IPO March 30, 2026.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730785</guid>
      <pubDate>Tue, 28 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730785-ribo-diagens-tally-2-hong-kong-biotech-medtech-ipos-in-q1-2026</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Hong-Kong-HKEX.webp?t=1588782956" type="image/png" medium="image" fileSize="582891">
        <media:title type="plain">Hong Kong stock market illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Ribo, Diagens tally 2 Hong Kong biotech, medtech IPOs in Q1 2026 </title>
      <description>
        <![CDATA[Ribo Life Science Co. Ltd.’s HK$1.8 billion (US$230 million) raise on Jan. 9 was the sole Chinese biotech IPO on the Hong Kong Stock Exchange in the first quarter (Q1) of 2026, despite a growing backlog of more than 70 filings from China life science firms in 2025. Among med-tech companies, Hangzhou Diagens Biotechnology Co. Ltd. debuted with a $101 million Hong Kong IPO March 30, 2026.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730619</guid>
      <pubDate>Fri, 24 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730619-ribo-diagens-tally-2-hong-kong-biotech-medtech-ipos-in-q1-2026</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Hong-Kong-HKEX.webp?t=1588782956" type="image/png" medium="image" fileSize="582891">
        <media:title type="plain">Hong Kong stock market illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Financing at Vivatides to advance extrahepatic RNA therapeutics</title>
      <description>
        <![CDATA[Vivatides Therapeutics Inc. has closed an oversubscribed $54 million series A financing to advance its work in extrahepatic RNA delivery technologies. Proceeds from the financing will be used to further advance the company’s extrahepatic delivery platform and accelerate pipeline programs.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730327</guid>
      <pubDate>Mon, 13 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730327-financing-at-vivatides-to-advance-extrahepatic-rna-therapeutics</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/Dollar-sign-between-hands.webp?t=1740610521" type="image/jpeg" medium="image" fileSize="123345">
        <media:title type="plain">Dollar sign between hands</media:title>
      </media:content>
    </item>
    <item>
      <title>China’s NMPA clears China Medical System’s CMS-D008 for clinic</title>
      <description>
        <![CDATA[China Medical System Holdings Ltd. has received clinical trial approval from China’s National Medical Products Administration (NMPA) for CMS-D008 injection for overweight or obese individuals.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729394</guid>
      <pubDate>Fri, 06 Mar 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729394-chinas-nmpa-clears-china-medical-systems-cms-d008-for-clinic</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/RNA-3D-illustration.webp?t=1725482193" type="image/jpeg" medium="image" fileSize="212050">
        <media:title type="plain">3D illustration of RNA</media:title>
      </media:content>
    </item>
    <item>
      <title>GSK nabs two Frontier Biotech siRNA assets in $1B deal </title>
      <description>
        <![CDATA[GSK plc will pay Frontier Biotechnologies Inc. $40 million up front and up to $963 million in milestone payments to license two of Frontier’s small interfering RNA-based assets in the field of immunology. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/729316</guid>
      <pubDate>Tue, 03 Mar 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729316-gsk-nabs-two-frontier-biotech-sirna-assets-in-1b-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/siRNA-structure-model.webp?t=1732119622" type="image/jpeg" medium="image" fileSize="568771">
        <media:title type="plain">Illustration of siRNA structure</media:title>
      </media:content>
    </item>
    <item>
      <title>Atrium Tx launches with Avidity's RNA ticker and cardio assets </title>
      <description>
        <![CDATA[Targeting rare cardiomyopathy conditions with no approved disease-modifying therapies, Atrium Therapeutics Inc. started operations in San Diego, assuming the public listing and technology once held by Avidity Biosciences Inc., an RNA company acquired by Novartis AG for about $12 billion. Novartis closed the M&A, announced last October, as Atrium unveiled its pipeline and a $270 million cash position.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729314</guid>
      <pubDate>Mon, 02 Mar 2026 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729314-atrium-tx-launches-with-aviditys-rna-ticker-and-cardio-assets</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/heart-DNA-gene-therapy.webp?t=1721919232" type="image/png" medium="image" fileSize="381487">
        <media:title type="plain">Illustration of human heart with DNA structure background</media:title>
      </media:content>
    </item>
    <item>
      <title>Atrium Tx launches with Avidity's RNA ticker and cardio assets </title>
      <description>
        <![CDATA[Targeting rare cardiomyopathy conditions with no approved disease-modifying therapies, Atrium Therapeutics Inc. started operations in San Diego, assuming the public listing and technology once held by Avidity Biosciences Inc., an RNA company acquired by Novartis AG for about $12 billion. Novartis closed the M&A, announced last October, as Atrium unveiled its pipeline and a $270 million cash position.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729256</guid>
      <pubDate>Fri, 27 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729256-atrium-tx-launches-with-aviditys-rna-ticker-and-cardio-assets</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/heart-DNA-gene-therapy.webp?t=1721919232" type="image/png" medium="image" fileSize="381487">
        <media:title type="plain">Illustration of human heart with DNA structure background</media:title>
      </media:content>
    </item>
    <item>
      <title>GSK nabs two Frontier Biotech siRNA assets in $1B deal </title>
      <description>
        <![CDATA[GSK plc will pay Frontier Biotechnologies Inc. $40 million up front and up to $963 million in milestone payments to license two of Frontier’s small interfering RNA-based assets in the field of immunology. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/729206</guid>
      <pubDate>Wed, 25 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729206-gsk-nabs-two-frontier-biotech-sirna-assets-in-1b-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/siRNA-structure-model.webp?t=1732119622" type="image/jpeg" medium="image" fileSize="568771">
        <media:title type="plain">Illustration of siRNA structure</media:title>
      </media:content>
    </item>
    <item>
      <title>GSK licenses Frontier Biotechnologies’ siRNA therapeutics </title>
      <description>
        <![CDATA[Frontier Biotechnologies Inc. has entered into an exclusive licensing agreement with GSK plc whereby GSK will obtain exclusive worldwide rights to develop, manufacture and commercialize two of Frontier’s small interfering RNA (siRNA) pipeline products.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729033</guid>
      <pubDate>Wed, 25 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729033-gsk-licenses-frontier-biotechnologies-sirna-therapeutics</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Nephrology/kidney-genetic-congenital.webp?t=1709655526" type="image/jpeg" medium="image" fileSize="168177">
        <media:title type="plain">Illustration of kidney with DNA structures</media:title>
      </media:content>
    </item>
    <item>
      <title>Madrigal licenses six Ribo siRNA programs</title>
      <description>
        <![CDATA[Madrigal Pharmaceuticals Inc. has signed an exclusive global license agreement with Suzhou Ribo Life Science Co. Ltd. and its subsidiary Ribocure Pharmaceuticals AB for six preclinical small interfering RNA (siRNA) programs.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728784</guid>
      <pubDate>Wed, 11 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728784-madrigal-licenses-six-ribo-sirna-programs</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/siRNA.webp?t=1590081687" type="image/png" medium="image" fileSize="147005">
        <media:title type="plain">siRNA bound to mRNA</media:title>
      </media:content>
    </item>
    <item>
      <title>Genentech licenses Sanegene’s RNAi asset in $1.7B deal</title>
      <description>
        <![CDATA[Genentech Inc. is paying $200 million up front and up to $1.5 billion in milestone payments to license one of Suzhou Sanegene Bio Inc.’s RNAi programs. Metabolic and autoimmune-focused Sanegene did not disclose specifics around the licensed candidate, except that it was derived from its LEAD (Ligand and Enhancer Assisted Delivery) platform.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728517</guid>
      <pubDate>Tue, 03 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728517-genentech-licenses-sanegenes-rnai-asset-in-17b-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Interfering-RNA-(RNAi).webp?t=1750428815" type="image/jpeg" medium="image" fileSize="504763">
        <media:title type="plain">Interfering RNA (RNAi)</media:title>
      </media:content>
    </item>
    <item>
      <title>Repertoire Decodes autoimmunity in $1.92B Eli Lilly deal</title>
      <description>
        <![CDATA[In its fourth major biopharma deal since its 2019 founding, Repertoire Immune Medicines signed a partnership with Eli Lilly and Co. to develop tolerizing therapies for several autoimmune diseases, gaining an up-front payment of $85 million, with a potential $1.84 billion in development and commercial milestone payments coming later, along with tiered royalties.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728474</guid>
      <pubDate>Thu, 29 Jan 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728474-repertoire-decodes-autoimmunity-in-192b-eli-lilly-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/T-cells2.webp?t=1588881096" type="image/png" medium="image" fileSize="517011">
        <media:title type="plain">T cells </media:title>
      </media:content>
    </item>
    <item>
      <title>Blocking TET3 disrupts OTX2 effects in group 3 medulloblastoma</title>
      <description>
        <![CDATA[Medulloblastoma is one of the most common pediatric brain malignancies. A deeper understanding of the mechanisms underlying tumor cell fate determination is crucial to develop novel, effective and safe therapeutic strategies. With this aim, researchers from the University of Chinese Academy of Sciences and collaborating institutions recently conducted a study integrating whole-genome bisulfite sequencing and bulk RNA sequencing (RNA-seq) data from 189 human medulloblastoma samples.]]>
      </description>
      <guid>http://www.bioworld.com/articles/728006</guid>
      <pubDate>Thu, 15 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/728006-blocking-tet3-disrupts-otx2-effects-in-group-3-medulloblastoma</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Cancer-research-microscope-pathology.webp?t=1669740694" type="image/png" medium="image" fileSize="1333240">
        <media:title type="plain">Microscope with laptop displaying histology image.</media:title>
      </media:content>
    </item>
    <item>
      <title>Sarepta Therapeutics seeks clinical trial clearance for SRP-1005</title>
      <description>
        <![CDATA[Sarepta Therapeutics Inc. has filed a clinical trial application (CTA) in New Zealand seeking clearance to initiate a first-in-human trial of SRP-1005 (formerly ARO-HTT). Pending approval, the INSIGHTT trial is anticipated to begin in the second quarter of this year.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727748</guid>
      <pubDate>Thu, 08 Jan 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727748-sarepta-therapeutics-seeks-clinical-trial-clearance-for-srp-1005</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/3D-illustration-of-RNA-and-proteins.webp?t=1738099271" type="image/jpeg" medium="image" fileSize="124015">
        <media:title type="plain">3D illustration of RNA and proteins</media:title>
      </media:content>
    </item>
    <item>
      <title>Obesity rings in New Year with Lilly-Nimbus $1.3B deal, RNAi data</title>
      <description>
        <![CDATA[Biopharma industry zeal for obesity therapeutics does not appear to be dying down any time soon, with Eli Lilly and Co. entering a $1.3 billion deal with Nimbus Therapeutics LLC for a new small molecule, and Arrowhead Pharmaceuticals Inc. rolling out phase I/IIa data of its RNAi therapeutics used in combination with Lilly’s GLP-1/GIP receptor agonist tirzepatide.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727696</guid>
      <pubDate>Tue, 06 Jan 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727696-obesity-rings-in-new-year-with-lilly-nimbus-13b-deal-rnai-data</link>
    </item>
    <item>
      <title>Rona Therapeutics seeks clinical trial clearance for RN-5681</title>
      <description>
        <![CDATA[Rona Therapeutics Co. Ltd. has announced the submission of RN-5681 to the Australian Human Research Ethics Committee (HREC), and anticipates dosing to begin in a phase I trial in the first quarter of next year.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727265</guid>
      <pubDate>Thu, 18 Dec 2025 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727265-rona-therapeutics-seeks-clinical-trial-clearance-for-rn-5681</link>
    </item>
    <item>
      <title>Bispecific siRNA knocks down YAP1, WWTR1 with single guide strand</title>
      <description>
        <![CDATA[Yes-associated protein (YAP), encoded by Yes1-associated transcriptional regulator (YAP1) and transcriptional coactivator with PDZ-binding motif (TAZ), encoded by WW domain containing transcription regulator 1 (WWTR1), are two crucial paralog transcriptional regulators of the Hippo pathway regulating organ size, tissue homeostasis and disease progression.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727134</guid>
      <pubDate>Mon, 15 Dec 2025 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727134-bispecific-sirna-knocks-down-yap1-wwtr1-with-single-guide-strand</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Liver-on-digital-lens.webp?t=1709588066" type="image/jpeg" medium="image" fileSize="175206">
        <media:title type="plain">Liver over digital lens background</media:title>
      </media:content>
    </item>
    <item>
      <title>Peptidream reveals milestone in Alnylam collaboration</title>
      <description>
        <![CDATA[Peptidream Inc. has announced a preclinical development milestone in its collaboration with Alnylam Pharmaceuticals Inc. under their siRNA conjugate discovery collaboration.]]>
      </description>
      <guid>http://www.bioworld.com/articles/727129</guid>
      <pubDate>Mon, 15 Dec 2025 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/727129-peptidream-reveals-milestone-in-alnylam-collaboration</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/siRNA-structure-model.webp?t=1732119622" type="image/jpeg" medium="image" fileSize="568771">
        <media:title type="plain">Illustration of siRNA structure</media:title>
      </media:content>
    </item>
    <item>
      <title>Junevity raises funds to advance siRNA metabolism program</title>
      <description>
        <![CDATA[Junevity Inc. has raised $10 million in new funding, bringing its seed financing to a total of $20 million. The new funding will enable Junevity to advance JUN-01, its lead siRNA program for type 2 diabetes and obesity, through IND-enabling and initial clinical studies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726804</guid>
      <pubDate>Thu, 04 Dec 2025 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726804-junevity-raises-funds-to-advance-sirna-metabolism-program</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Endocrine-Metabolic-glucose-bloodstream.webp?t=1674056639" type="image/png" medium="image" fileSize="1313266">
        <media:title type="plain">Illustration of glucose molecules in a bloodstream</media:title>
      </media:content>
    </item>
    <item>
      <title>Tangram seeks clinical trial clearance for TGM-312 for MASH</title>
      <description>
        <![CDATA[Tangram Therapeutics plc has submitted a clinical trial application (CTA) to the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) to initiate a phase I/II trial of TGM-312 for metabolic dysfunction-associated steatohepatitis (MASH).]]>
      </description>
      <guid>http://www.bioworld.com/articles/726567</guid>
      <pubDate>Wed, 26 Nov 2025 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726567-tangram-seeks-clinical-trial-clearance-for-tgm-312-for-mash</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/fatty-liver-disease.webp?t=1589217291" type="image/png" medium="image" fileSize="932342">
        <media:title type="plain">Liver disease</media:title>
      </media:content>
    </item>
    <item>
      <title>Arrowhead’s plozasiran cleared for FCS; Ionis patent duel awaits</title>
      <description>
        <![CDATA[Arrowhead Pharmaceuticals Inc. won U.S. FDA approval of plozasiran in familial chylomicronemia syndrome (FCS), the second drug to gain clearance for use in the rare genetic disease following the late 2024 nod for Ionis Pharmaceuticals Inc.’s Tryngolza (olezarsen), setting up a battle in the marketplace even as the firms wage a patent dispute regarding the two RNA-based therapies.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726374</guid>
      <pubDate>Tue, 18 Nov 2025 15:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726374-arrowheads-plozasiran-cleared-for-fcs-ionis-patent-duel-awaits</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Redemplo.webp?t=1763500052" type="image/jpeg" medium="image" fileSize="366924">
        <media:title type="plain">Redemplo packaging</media:title>
        <media:description type="plain">Credit: Arrowhead Pharmaceuticals Inc.</media:description>
      </media:content>
    </item>
    <item>
      <title>City Therapeutics seeks clinical trial clearance for CITY-FXI</title>
      <description>
        <![CDATA[City Therapeutics Inc. has submitted a clinical trial application (CTA) to the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) to initiate a phase I study of CITY-FXI, an investigational RNAi therapeutic targeting factor XI (FXI) for the treatment of thromboembolic diseases.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726059</guid>
      <pubDate>Tue, 11 Nov 2025 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726059-city-therapeutics-seeks-clinical-trial-clearance-for-city-fxi</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cardiovascular/Thrombosis-blood-clot.webp?t=1676651893" type="image/png" medium="image" fileSize="1702000">
        <media:title type="plain">Illustration of clot forming in blood vessel</media:title>
      </media:content>
    </item>
    <item>
      <title>Lilly moves deeper into RNAi with $1.2B Sanegene obesity deal</title>
      <description>
        <![CDATA[In a deal worth $1.2 billion, Suzhou Sanegene Bio Inc. and Eli Lilly and Co. are partnering to advance RNAi candidates for metabolic diseases based on Sanegene's tissue selective delivery technology.]]>
      </description>
      <guid>http://www.bioworld.com/articles/726150</guid>
      <pubDate>Tue, 11 Nov 2025 00:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/726150-lilly-moves-deeper-into-rnai-with-12b-sanegene-obesity-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/RNA-strand.webp?t=1609964773" type="image/png" medium="image" fileSize="440899">
        <media:title type="plain">RNA strand</media:title>
      </media:content>
    </item>
  </channel>
</rss>
